Heidelberg Pharma AG (HPHA) - Total Assets
Based on the latest financial reports, Heidelberg Pharma AG (HPHA) holds total assets worth €62.45 Million EUR (≈ $73.02 Million USD) as of May 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Heidelberg Pharma AG investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Heidelberg Pharma AG - Total Assets Trend (2016–2024)
This chart illustrates how Heidelberg Pharma AG's total assets have evolved over time, based on quarterly financial data. Check Heidelberg Pharma AG (HPHA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Heidelberg Pharma AG - Asset Composition Analysis
Current Asset Composition (November 2024)
Heidelberg Pharma AG's total assets of €62.45 Million consist of 78.3% current assets and 21.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 48.5% |
| Accounts Receivable | €284.00K | 0.5% |
| Inventory | €11.16 Million | 18.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.75 Million | 4.5% |
| Goodwill | €6.11 Million | 10.1% |
Asset Composition Trend (2016–2024)
This chart illustrates how Heidelberg Pharma AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Heidelberg Pharma AG stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Heidelberg Pharma AG's current assets represent 78.3% of total assets in 2024, an increase from 32.7% in 2016.
- Cash Position: Cash and equivalents constituted 48.5% of total assets in 2024, up from 30.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, a decrease from 58.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 18.4% of total assets.
Heidelberg Pharma AG Competitors by Total Assets
Key competitors of Heidelberg Pharma AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Heidelberg Pharma AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.74 | 6.13 | 1.97 |
| Quick Ratio | 5.73 | 4.90 | 1.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €42.85 Million | €49.01 Million | €6.47 Million |
Heidelberg Pharma AG - Advanced Valuation Insights
This section examines the relationship between Heidelberg Pharma AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.37 |
| Latest Market Cap to Assets Ratio | 2.30 |
| Asset Growth Rate (YoY) | -13.7% |
| Total Assets | €60.72 Million |
| Market Capitalization | $139.89 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Heidelberg Pharma AG's assets at a significant premium (2.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Heidelberg Pharma AG's assets decreased by 13.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Heidelberg Pharma AG (2016–2024)
The table below shows the annual total assets of Heidelberg Pharma AG from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-11-30 | €60.72 Million ≈ $70.99 Million |
-13.69% |
| 2023-11-30 | €70.35 Million ≈ $82.25 Million |
-30.05% |
| 2022-11-30 | €100.58 Million ≈ $117.59 Million |
+362.83% |
| 2021-11-30 | €21.73 Million ≈ $25.41 Million |
+10.83% |
| 2020-11-30 | €19.61 Million ≈ $22.92 Million |
-14.71% |
| 2019-11-30 | €22.99 Million ≈ $26.88 Million |
-26.29% |
| 2018-11-30 | €31.19 Million ≈ $36.47 Million |
-24.82% |
| 2017-11-30 | €41.49 Million ≈ $48.51 Million |
+172.22% |
| 2016-11-30 | €15.24 Million ≈ $17.82 Million |
-- |
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amaniti… Read more